Company Filing History:
Years Active: 2016
Title: Michael Kenneth Gilson: Innovator in Pharmaceutical Compositions
Introduction
Michael Kenneth Gilson is a notable inventor based in San Diego, California. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compositions and methods for inhibiting proteases. His work has the potential to impact various medical conditions, including viral infections and cancers.
Latest Patents
Gilson holds a patent for "Compositions and methods for inhibiting proteases." This invention focuses on pharmaceutical compounds and formulations that include a family of epoxyketone compounds. These compounds can be utilized in treating, preventing, or ameliorating conditions such as HIV-1 infection, immune disorders, neurodegenerative diseases, and various types of cancer.
Career Highlights
Michael Kenneth Gilson is affiliated with the University of California, where he continues to advance his research in pharmaceutical innovations. His work emphasizes the importance of developing effective treatments for serious health conditions through innovative chemical compositions.
Collaborations
Gilson has collaborated with esteemed colleagues, including William H. Gerwick and Alban R. Pereira-Badilla. These partnerships have contributed to the depth and breadth of his research efforts.
Conclusion
Michael Kenneth Gilson is a prominent figure in the field of pharmaceutical inventions, with a focus on protease inhibition. His contributions are paving the way for new treatments that could significantly improve patient outcomes.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.